Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4LJO9
|
|||
| Drug Name |
CLG561
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Geographic retinal atrophy [ICD-11: 9B78.9] | Phase 2 | [1] | |
| Company |
Alcon
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Complement factor P (CFP) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02515942) CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA). U.S. National Institutes of Health. | |||
| REF 2 | Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.